-
PTC Therapeutics signs lease with Bristol-Myers Squibb — 3 insights
PTC Therapeutics is leasing a 185,000-square-foot biologics-focused research space from Bristol-Myers Squibb, BioPharmaReport.com reports. -
A timeline of the California Institute for Regenerative Medicine
The California Institute for Regenerative Medicine has been instrumental in stem cell research since it was first established in 2004, but it faces closure in 2022 if a ballot initiative to get it more funding is unsuccessful. -
DiscGenics treats 1st patients in degenerative disc disease cell therapy trial — 3 insights
Discgenics treated the first patients in its clinical trial of intervertebral disc tissue for mild to moderate degenerative disc disease in Japan, reports Biospectrum Asia. -
Dr. Andreas Gomoll performs cartilage repair implantations at Hospital for Special Surgery
Andreas Gomoll, MD, implanted Cartiheal's Agili-C in two patients in an investigational device exemption study at Hospital for Special Surgery in New York City. -
NanoFUSE Biologics to crack Panama market — 3 things to know
NanoFuse Biologics is launching its biologic in Panama City, Panama, through a partnership with medical distributor PTY Medical Group. -
Camber Spine delves into biologics with portfolio expansion
Camber Spine is widening its portfolio by tapping into the biologics market. -
Biologics company adds Dr. Michael May to board
Biologics development company AgeX Therapeutics added Michael May, PhD, to its board of directors, returning it to full strength. -
Dr. Chad Kurtenbach, Sanford Health tests healing power of stem cells in osteoarthritis — 4 points
Chad Kurtenbach, MD, of Sioux Falls, S.D.-based Sanford Health is conducting a study of a stem cell treatment for patients with osteoarthritis in the knee. -
The next orthopedic revolution — Andrews' Dr. Steve Jordan on biologics
Biologics has the potential to be the next transformative tool in the orthopedic surgeon's playbook, but the field still has a ways to go before it becomes a mainstream medicinal offering. -
Health plan provides access to regenerative orthopedic procedures through partnership
Health plan provider Gilsbar entered into a partnership with interventional orthopedic clinic network Regenexx to provide beneficiaries access to reduced-cost musculoskeletal care options. -
Closing no more? Ballot initiative could grant California stem cell institute continued life
The California Institute for Regenerative Medicine was never supposed to last infinitely, but a new ballot initiative could extend its lifespan, Nature reports. -
Investor-backed company creates biologic product for spine, orthopedics — 3 insights
NanoFuse released NanoStrip, a glass synthetic biologic strip clinicians can use in spine and orthopedic procedures. -
Biologics company gets FDA approval to study adipose-derived stem cell treatment — 4 insights
The FDA approved Personalized Stem Cells' new drug application for its adipose-derived stem cell-based osteoarthritis treatment. -
Stem cell treatment targets, eradicates bone cancer metastases in mice — 4 insights
A team of UC Irvine researchers developed a mesenchymal stem cell-based treatment that can identify and kill bone cancer metastases in mice, the Daily Pilot reports. -
Dr. Adam Rivadeneyra: The promise of biologics + threat of 'bad information'
Adam Rivadeneyra, MD, a sports medicine specialist with Irvine, Calif.-based Hoag Orthopedic Institute, spoke to Becker's Spine Review about his predictions for the field of biologics. -
NanoFUSE Biologics cracks Asian market with successful procedure in Thailand
NanoFuse Biologics expanded into Asia after the successful use of its technology in a patient suffering from degenerative spine disease and osteoporosis in Thailand. -
DiscGenics tests injectable disc cell therapy for degenerative disc disease
Biotechnology company DiscGenics treated the first Utahns in its nationwide clinical study of injectable disc cell therapy for degenerative disc disease. -
California Institute for Regenerative Medicine expected to run out of money — 4 insights
The California Institute for Regenerative Medicine could close after awarding all allocated funds, The Scientist reports. -
Federal court bans Florida stem cell company from treating patients, including spinal cord injury
A federal court ordered that Sunrise, Fla.-based regenerative medicine companies US Stem Cell Clinic and US Stem Cell stop providing stem cell treatments to patients, according to the U.S. Department of Justice. -
NervGen Pharma launches MS program focusing on nerve remyelination — 3 things to know
NervGen Pharma will use its developing drug technology for spinal cord injuries in a new multiple sclerosis program.
Page 17 of 34